X0607 3 2026-07-16 0 0001980845 enGene Therapeutics Inc. ENGN 0002145406 Richton Kathleen P. true C/O 4868 RUE LEVY, SUITE 220 SAINT-LAURENT A8 H4R 2P1 QUEBEC, CANADA true SVP, Finance and Treasurer Common Shares 6900 D Stock Option (Right to Buy) 7.39 2035-01-29 Common Shares 45000 D Stock Option (Right to Buy) 9.53 2036-01-30 Common Shares 13900 D Stock Option (Right to Buy) 1.75 2036-06-16 Common Shares 105000 D Consists of 6,900 unvested restricted stock units (RSUs) granted to the Reporting Person on January 30, 2026 pursuant to the Issuer's Amended and Restated 2023 Incentive Equity Plan (the "Plan"), which are scheduled to vest annually in substantially equal amounts for four years, commencing January 15, 2027, subject to the Reporting Person's continued service. Each RSU represents a contingent right to receive one common share of the Issuer. Non-qualified stock option grant awarded as an inducement award outside of the Plan in accordance with NASDAQ Listing Rule 5635(c)(4). This option vested at 25% on January 27, 2026, with the remaining portion to vest monthly in substantially equal amounts for the following 36 months, subject to the Reporting Person's continued service. This option vests monthly in substantially equal amounts for 48 months, commencing January 30, 2026, subject to the Reporting Person's continued service. This option vests monthly in substantially equal amounts for 48 months, commencing June 16, 2026, subject to the Reporting Person's continued service. Exhibit 24 - Power of Attorney /s/ Kathleen P. Richton 2026-07-22